Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Geniculate Artery Embolization for Recurrent Effusion After Total Knee Arthroplasty in a Patient With Hemophilia.

Cureus·2026
Same author

Emergency mitral valve transcatheter edge-to-edge repair in cardiogenic shock due to papillary muscle rupture.

Journal of cardiology cases·2026
Same author

Stem Cell and Cell-Free Strategies for Osteoarthritis: Toward Durable Regenerative Therapies.

Stem cells international·2026
Same author

Control of cell division by an <i>Acinetobacter baumannii</i> protein with a novel nucleotidyl-cyclase-like fold.

bioRxiv : the preprint server for biology·2026
Same author

Survival Outcomes of Cabazitaxel or Subsequent Androgen Receptor Pathway Inhibitor (ARPI) in Post-Docetaxel/ARPI Metastatic Castration-Resistant Prostate Cancer.

Clinical genitourinary cancer·2026
Same author

Urgent Transcatheter Edge-To-Edge Mitral Valve Repair in Cardiogenic Shock: A Case Series.

A&A practice·2026
Same journal

Eugene Braunwald, MD, 1929-2026.

Circulation·2026
Same journal

AHA/ACC/ESC/WHF Expert Consensus Document: Second Universal Definition of Heart Failure (2026).

Circulation·2026
Same journal

Advancing Quality in the Evaluation, Surveillance, and Management of Aortic Stenosis: A Report From the AHA Target: AS Registry.

Circulation·2026
Same journal

Heart Failure Occurring in the Perinatal Period: A Scientific Statement From the American Heart Association.

Circulation·2026
Same journal

Correction to: 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

Circulation·2026
Same journal

Correction to: The Natural History of Massive Left Ventricular Hypertrophy in Pediatric Hypertrophic Cardiomyopathy: A Multiregistry Analysis.

Circulation·2026
関連記事をすべて見る

関連する実験動画

Updated: May 13, 2026

Gene Transfer for Ischemic Heart Failure in a Preclinical Model
07:35

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

多様性細胞ベースの遺伝子治療で心室機能を最大化します.

Terrence M Yau1, Christopher Kim, Guangming Li

  • 1Division of Cardiovascular Surgery, Toronto General Hospital, Department of Surgery, University of Toronto, Heart & Stroke Foundation/Richard Lewar Centre of Excellence, Toronto, Ontario, Canada. terry.yau@utoronto.ca

Circulation
|September 15, 2005
PubMed
まとめ
この要約は機械生成です。

この研究は,血管内皮成長因子 (VEGF) とインスリン類似成長因子I (IGF-I) 遺伝子治療と骨髄細胞 (BMC) 移植を組み合わせて,心臓の機能を改善することを示しています. このマルチモダルのアプローチは,細胞生存を向上させ,心筋の細胞死亡を減少させます.

さらに関連する動画

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes
09:16

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes

Published on: June 3, 2018

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment
08:24

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment

Published on: May 25, 2020

関連する実験動画

Last Updated: May 13, 2026

Gene Transfer for Ischemic Heart Failure in a Preclinical Model
07:35

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes
09:16

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes

Published on: June 3, 2018

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment
08:24

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment

Published on: May 25, 2020

科学分野:

  • 心血管研究 循環器科の研究
  • 再生医学は,再生医療である.
  • 遺伝子療法の遺伝子治療法

背景:

  • 血管内皮成長因子 (VEGF) は,心筋の傷跡における血管新生を促進します.
  • インスリン類似成長因子I (IGF-I) は,高縮を促し,アポプトシスを阻害する可能性があります.
  • 骨髄細胞 (BMC) 移植は,心臓損傷に対する潜在的な治療法です.

研究 の 目的:

  • 細胞ベースのIGF-IおよびVEGFマルチゲン療法の有効性を評価する.
  • 左心室 (LV) 機能,細胞生存,アポトーシスへの影響を評価する.
  • ネズミの心筋梗塞モデルで,BMC移植後のメリットを決定する.

主な方法:

  • 誘発性心筋梗塞を患ったルイス・ラットは,VEGF,IGF-I,またはその両方を発現させるように設計されたBMCを受け取った.
  • 遺伝子発現,細胞生存,アポトーシス,およびLV機能は4週間にわたって定量化されました.
  • テクニックには,リアルタイムPCR,TUNEL染色,エコーカルディオグラフィー,ウェスタンブラッティングが含まれていました.

主要な成果:

  • BMCにおけるVEGFとIGF-Iの共発は,傷痕組織におけるIGF-IとVEGFのレベルを著しく増加させた.
  • 移植細胞生存率は,VEGF+IGF-I群で最高でした.
  • アポトーシスは減少し,LVエジェクション分子は,対照群と単一遺伝子治療群と比較して,併用遺伝子治療群で有意に改善されました.

結論:

  • VEGFとIGF-Iの両方を発現するBMCの移植は,アポトーシスを効果的に減らし,移植細胞の生存率を高めます.
  • この多様式,細胞ベースの遺伝子治療アプローチは,心筋梗塞後の左心室機能の回復を最大化します.
  • 併用遺伝子療法は,心臓病に対する細胞移植戦略の成果を改善する見込みがある.